Posted by Michael Wonder on 17 Jul 2026
Apnimed announces FDA acceptance of new drug application for AD109, an investigational oral pill to treat adults with obstructive sleep apnoea
14 July 2026 - Apnimed today announced that the US FDA has accepted for review the new drug application filing of AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) for the treatment of adults with obstructive sleep apnoea.
The FDA has assigned a PDUFA target action date of 28 February 2027.
